Perrigo Company plc (NYSE:PRGO) Receives Consensus Recommendation of “Hold” from Analysts

Perrigo Company plc (NYSE:PRGO) has been assigned a consensus recommendation of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $19.3333.

A number of research firms have recently weighed in on PRGO. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Canaccord Genuity Group dropped their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Weiss Ratings downgraded Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a report on Thursday, February 26th.

Perrigo Trading Down 4.0%

PRGO stock opened at $11.15 on Wednesday. The company has a market cap of $1.54 billion, a P/E ratio of -0.85, a PEG ratio of 1.37 and a beta of 0.51. Perrigo has a twelve month low of $9.23 and a twelve month high of $28.43. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. The business has a fifty day moving average of $11.15 and a 200-day moving average of $12.48.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $841.80 million during the quarter, compared to the consensus estimate of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities research analysts expect that Perrigo will post 2.12 EPS for the current year.

Perrigo Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Investors of record on Friday, May 29th will be issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 10.4%. The ex-dividend date is Friday, May 29th. Perrigo’s dividend payout ratio is currently -8.85%.

Institutional Investors Weigh In On Perrigo

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRGO. Amundi increased its holdings in Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Perrigo by 126.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after purchasing an additional 647,982 shares during the last quarter. United Services Automobile Association bought a new stake in Perrigo in the first quarter valued at about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Perrigo by 6.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after purchasing an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its holdings in Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.